[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2493474T - Métodos e composições para libertação prolongada de fármacos - Google Patents

Métodos e composições para libertação prolongada de fármacos

Info

Publication number
PT2493474T
PT2493474T PT108275306T PT10827530T PT2493474T PT 2493474 T PT2493474 T PT 2493474T PT 108275306 T PT108275306 T PT 108275306T PT 10827530 T PT10827530 T PT 10827530T PT 2493474 T PT2493474 T PT 2493474T
Authority
PT
Portugal
Prior art keywords
drugs
compositions
methods
sustained delivery
sustained
Prior art date
Application number
PT108275306T
Other languages
English (en)
Inventor
Nanduri Padma
Aaron Dyer T
Original Assignee
Intratus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intratus Inc filed Critical Intratus Inc
Publication of PT2493474T publication Critical patent/PT2493474T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
PT108275306T 2009-10-30 2010-10-29 Métodos e composições para libertação prolongada de fármacos PT2493474T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25661409P 2009-10-30 2009-10-30
US28947109P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
PT2493474T true PT2493474T (pt) 2019-11-26

Family

ID=43923004

Family Applications (1)

Application Number Title Priority Date Filing Date
PT108275306T PT2493474T (pt) 2009-10-30 2010-10-29 Métodos e composições para libertação prolongada de fármacos

Country Status (13)

Country Link
US (3) US20110104083A1 (pt)
EP (3) EP2493474B1 (pt)
CY (1) CY1122417T1 (pt)
DK (1) DK2493474T3 (pt)
ES (1) ES2752008T3 (pt)
HR (1) HRP20191828T1 (pt)
HU (1) HUE046071T2 (pt)
LT (1) LT2493474T (pt)
PL (1) PL2493474T3 (pt)
PT (1) PT2493474T (pt)
RS (1) RS59483B1 (pt)
SI (1) SI2493474T1 (pt)
WO (2) WO2011053801A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2493474T (pt) * 2009-10-30 2019-11-26 Intratus Inc Métodos e composições para libertação prolongada de fármacos
DK2552449T3 (en) 2010-03-26 2017-06-19 Galderma Res & Dev COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
US8900626B2 (en) * 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
JP2014518275A (ja) * 2011-06-29 2014-07-28 インサイト・ビジョン・インコーポレイテッド 再発性マイボーム腺障害の処置方法およびそれによる再発頻度の減少方法
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
US20130045269A1 (en) * 2011-08-18 2013-02-21 Sorush LLC Formulations and methods for wound treatment
US20130251783A1 (en) * 2011-09-14 2013-09-26 Universitat Heidelberg Liposomes containing permeation enhancers for oral drug delivery
KR20140091543A (ko) 2011-10-19 2014-07-21 갈데르마 소시에떼아노님 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법
US20130303566A1 (en) * 2012-05-09 2013-11-14 David W. Hill Method for treating macular degeneration
JP2016510807A (ja) 2013-03-10 2016-04-11 ペリテック・ファーマ・リミテッドＰｅｒｉｔｅｃｈ Ｐｈａｒｍａ Ｌｔｄ． 局所組成物および局所障害の処置方法
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
US20140303166A1 (en) * 2013-04-08 2014-10-09 Gordon C. Tang Cosmetic method for changing the appearance of eyes
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
WO2015112776A2 (en) * 2014-01-22 2015-07-30 Marcio Marc Abreu Devices configured to provide treatment at an abreu brain thermal tunnel
DE102014203152A1 (de) * 2014-02-21 2015-08-27 Ursapharm Arzneimittel Gmbh Mikro- oder Nanoemulsion zur ophthalmologischen Anwendung
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
KR20240023714A (ko) * 2015-02-02 2024-02-22 산텐 세이야꾸 가부시키가이샤 폴리아프론 및 이의 안검 투여
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
WO2016178053A1 (en) * 2015-05-01 2016-11-10 Lozinsky Evgenia Compositions for the treatment of epistaxis
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
KR20180090251A (ko) * 2015-09-28 2018-08-10 아주라 오프탈믹스 엘티디 마이봄샘 지질 분비를 증가시키기 위한 티올 및 이황화물 함유 약제
EP3362096B1 (en) 2015-10-14 2023-12-13 Paul Gavaris Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
WO2017132410A1 (en) * 2016-01-26 2017-08-03 Frank Litvack Compositions and uses of alpha-adrenergic agents
CA3019349A1 (en) 2016-04-14 2017-10-19 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
CA3046228A1 (en) * 2016-12-23 2018-06-28 Kaleo, Inc. Medicament delivery device and methods for delivering drugs to infants and children
CN106963706A (zh) * 2017-03-17 2017-07-21 广州欧慕生物科技有限公司 一种眼部护理组合物及包含该组合物的药品和眼部护理品
CA3057569A1 (en) * 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
USD841152S1 (en) 2017-06-27 2019-02-19 Monica S. Naylor Eye drop container
JP2021501803A (ja) * 2017-11-03 2021-01-21 ブリエン ホールデン ビジョン インスティチュート リミテッド 近視の進行を制御し且つ／又は減少させるための医薬組成物
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US10695351B2 (en) * 2018-07-30 2020-06-30 Harrow Ip, Llc Pharmaceutical formulations for the treatment of dry eye and methods for fabricating and using thereof
WO2020047197A1 (en) * 2018-08-29 2020-03-05 Ocugen, Inc. Ophthalmic compositions and methods of use
WO2020051351A1 (en) * 2018-09-07 2020-03-12 Korwave, Llc Seizure detection system in mobile subjects
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
CA3151375A1 (en) * 2019-08-01 2021-02-04 Kushal Garima Ophthalmic composition of bevacizumab
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
MX2023002946A (es) * 2020-09-11 2023-04-11 Intratus Nevada Inc Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida.
AU2021381495A1 (en) 2020-11-23 2023-06-22 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
EP4284362A1 (en) * 2021-01-28 2023-12-06 Glaukos Corporation Formulations
TW202329958A (zh) * 2022-01-25 2023-08-01 張金明 西維美林水溶液組合物和使用方法
WO2023205695A1 (en) 2022-04-21 2023-10-26 Glaukos Corporation Ophthalmic topical cream compositions
US20230372303A1 (en) 2022-05-18 2023-11-23 Glaukos Corporation Applications of zwitterions in ophthalmic topical cream compositions and preparations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2703777A (en) * 1950-05-02 1955-03-08 Iso Sol Company Inc Ophthalmological preparations and vehicles and method of making the same
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
SE8701258D0 (sv) * 1987-03-26 1987-03-26 Pharmacia Ab A composition for the topical treatment of glaucoma or ocular hypertension
US5278142A (en) 1989-03-20 1994-01-11 Orbon Corporation Systemic delivery of polypeptides through the eye
JPH0551568A (ja) 1991-08-27 1993-03-02 Sekisui Chem Co Ltd アクリル系ホツトメルト接着剤組成物
JPH07228532A (ja) 1993-04-22 1995-08-29 Senju Pharmaceut Co Ltd 水性液剤、その有効成分の溶解性向上方法および安定化方法
JP3066561B2 (ja) 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
JP4489851B2 (ja) 1997-02-04 2010-06-23 千寿製薬株式会社 アリールカルボン酸の安定化方法、その安定化剤および安定化されたアリールカルボン酸からなる水性液剤
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
JP4591728B2 (ja) 1998-12-28 2010-12-01 大正製薬株式会社 眼精疲労改善用点眼剤
DE60011589T2 (de) 1999-03-26 2004-11-25 Pozen, Inc. Hochwirksame dihydroergotaminhaltige arzneizusammensetzungen
US6204270B1 (en) * 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
JP2001302518A (ja) * 2000-02-15 2001-10-31 Rohto Pharmaceut Co Ltd 官能改善方法および官能改善剤
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
JP4261912B2 (ja) * 2001-04-19 2009-05-13 テイカ製薬株式会社 薬剤および薬剤キット
JP2003055225A (ja) * 2001-08-16 2003-02-26 Rohto Pharmaceut Co Ltd 安定化された組成物
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
KR20130121196A (ko) * 2003-01-22 2013-11-05 센주 세이야꾸 가부시키가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환 치료약의 눈의 국소 조직으로의 이행 방법
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
DE602005019724D1 (de) * 2004-05-21 2010-04-15 Senju Pharma Co Ophthalmologische perkutan absorbierbare zubereitung enthaltend einen muscarin-rezeptor-agonist
JPWO2006087968A1 (ja) * 2005-02-17 2008-07-03 角治 東條 眼科用固形外用薬剤
WO2006102071A1 (en) 2005-03-18 2006-09-28 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin converting enzyme inhibitors, compositions and methods of use
US20060275232A1 (en) * 2005-06-01 2006-12-07 L'oreal Two-composition product, uses thereof, and makeup kit containing this product
US7381707B2 (en) * 2005-06-30 2008-06-03 Johnson & Johnson Consumer Companies, Inc. Treatment of dry eye
KR20080034916A (ko) 2005-07-08 2008-04-22 센주 세이야꾸 가부시키가이샤 에피나스틴을 포함하는 경피 흡수 안과 제제
EP1901708B1 (en) 2005-07-08 2013-09-11 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
KR20080031430A (ko) 2005-07-26 2008-04-08 센주 세이야꾸 가부시키가이샤 경피적으로 흡수가능한 안과용 제제
CN101355876B (zh) * 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
US20090136598A1 (en) * 2006-04-26 2009-05-28 Aciex, Inc. Compositions for the Treatment and Prevention of Eyelid Swelling
US20080020064A1 (en) * 2006-07-21 2008-01-24 Advanced Vision Research Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
JP2010502564A (ja) 2006-08-28 2010-01-28 千寿製薬株式会社 眼科用経皮吸収型製剤
EP2131809A2 (en) * 2007-02-28 2009-12-16 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions
EP3167886B1 (en) 2007-10-19 2020-08-05 Novartis AG Compositions and methods for treatment of macular edema
CN101969772A (zh) * 2007-10-31 2011-02-09 帕梅拉·立普金 前列腺素类似物组合物和治疗上皮相关症状的方法
PT2493474T (pt) 2009-10-30 2019-11-26 Intratus Inc Métodos e composições para libertação prolongada de fármacos

Also Published As

Publication number Publication date
US20110104206A1 (en) 2011-05-05
US20110104083A1 (en) 2011-05-05
WO2011053792A3 (en) 2011-09-22
RS59483B1 (sr) 2019-12-31
ES2752008T3 (es) 2020-04-02
US20150174211A1 (en) 2015-06-25
LT2493474T (lt) 2019-10-10
EP3569223A1 (en) 2019-11-20
WO2011053792A4 (en) 2011-11-24
US9034830B2 (en) 2015-05-19
CY1122417T1 (el) 2021-01-27
EP2493475A4 (en) 2014-10-29
WO2011053792A2 (en) 2011-05-05
WO2011053801A4 (en) 2011-11-10
PL2493474T3 (pl) 2020-03-31
SI2493474T1 (sl) 2019-11-29
WO2011053801A3 (en) 2011-09-29
HUE046071T2 (hu) 2020-01-28
EP2493474A4 (en) 2014-04-23
WO2011053801A2 (en) 2011-05-05
EP2493474A2 (en) 2012-09-05
EP2493474B1 (en) 2019-09-04
DK2493474T3 (da) 2019-10-14
EP2493475A2 (en) 2012-09-05
HRP20191828T1 (hr) 2019-12-27

Similar Documents

Publication Publication Date Title
IL276157A (en) Pharmaceutical preparations and methods for transferring them related to them
SI2493474T1 (sl) Postopki in sestavki za trajno dovajanje zdravil
HK1170679A1 (en) Compositions and methods for drug delivery
HK1250313A1 (zh) 穩定的藥物組合物和使用所述組合物的方法
EP2400851A4 (en) COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES
IL207569A0 (en) Compositions and methods for drug delivery
GB2478849A8 (en) Improved pharmaceutical compositions and methods of delivery
EP2643045A4 (en) THERAPEUTIC PROCESSES AND COMPOSITIONS FOR SOLID FORM DELIVERY
IL215608A0 (en) Drug delivery composition
IL195764A0 (en) Compositions and methods for drug delivery
ZA201109514B (en) Method of drug delivery
IL225485A0 (en) System and preparations for increased transport of medicine through the cheek tissue in the oral cavity
ZA201203060B (en) Composition and method of delivery
EP2440192A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTERING MATERIALS
IL219018A (en) Radzolid Pharmaceuticals and Uses
TWI371290B (en) Methods and compositions for enhancing transdermal drug delivery
EP2437735A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTERING SUBSTANCES